Hovione to buy Pfizer's Irish API facility
This article was originally published in Scrip
The Portuguese active pharmaceutical ingredient manufacturer Hovioneis to buyPfizer's Loughbeg API site in County Cork, Ireland, for an undisclosed sum. The deal should be completed by April 2009. Over the next two years Hovione Cork will validate processes for new compounds up for approval and will transfer products from its Loures site in Portugal. Between 70 and 80 employees will work at the plant, which will increase the company's manufacturing capacity by 427m3, up from 810m3. The new plant is equipped for low temperature chemistry and hydrogenation and also gives the company the capacity for producing spray-dried formulations. County Cork has the highest concentration of API production in the world, a good talent pool and a strong reputation for good manufacturing practices with health authorities, says the company. Hovione will continue to provide Pfizer with manufacturing services. IDA Ireland, the Industrial Development Agency, has welcomed the deal.
You may also be interested in...
Health technology assessment body NICE says that Revlimid fights cancer cells in a different way to current treatments which should help reduce resistance and improve disease outcomes.
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.
Brazil’s medicines regulator, ANVISA, finally has a new set of rules for the evaluation and marketing authorization of advanced therapy medicines.